Total revenues for 2025 increased by 6% to $9,026,938, up from $8,538,145 in 2024, primarily due to new customer acquisitions and expansion in existing accounts. Net loss for 2025 significantly widened to $2,470,399, compared to a net loss of $1,052,948 in 2024, largely due to an increase in the deferred tax asset valuation allowance. Operating loss improved slightly to $(1,230,020) in 2025 from $(1,408,217) in 2024. Research, development, and sustaining engineering expenses decreased by 4% to $2,152,843 in 2025, mainly due to reduced payments to outside contractors for SpinDetect development. General and administrative expenses rose by 11% to $1,388,160, primarily due to public company and legal expenses related to S-4 filings. Interest expense increased substantially to $119,190 in 2025 from $40,145 in 2024, driven by new subordinated debentures. Cash and cash equivalents decreased by $497,745, ending 2025 at $746,001. The company's merger agreement with Electronic Systems Technology, Inc. (ELST) was terminated in February 2026 after ELST shareholders did not provide the required approval. The rental property segment was discontinued effective June 30, 2025, with the company now occupying the entire premises for its operations. Development of the SpinDetect microfluidic detection platform is advancing, with beta testing expected to begin in 2026 and a commercial launch later in the year, focusing initially on oral-fluid delta-9-THC detection.